Incyte announced that the first patient has been treated in the Phase 3 TRuE-V clinical trial program evaluating the safety and efficacy of ruxolitinib cream as a monotherapy for adolescent and adult patients (age ≥12 years) with vitiligo.
Jazz Pharmaceuticals announced that its JZP-258 investigational medicine has met primary and key secondary endpoints in phase 3 narcolepsy trial.
Zealand Pharma announced that its dasiglucagon has met primary and all major secondary endpoints in paediatric phase 3 trial of severe hypoglycaemia.
Ipsen announced first results from the ENGAGE study which reports that simultaneous treatment with Dysport of both upper and lower limb spasticity in adult patients along with a Guided Self-rehabilitation Contract (GSC) – a personalized diary-based rehabilitation program – improved patients’ voluntary movement as measured by a composite active range of motion (CXA) outcome.
Clovis Oncology has entered into a global licensing and collaboration agreement with 3B Pharmaceuticals GmbH (3BP), a private German biotechnology company developing targeted radiopharmaceutical drugs and diagnostics for oncology indications with a high unmet medical need.
Cerevel Therapeutics said that a phase 2 trial assessing orally-administered tavapadon (formerly PF-06649751) in patients with early-stage Parkinson’s disease has met its primary endpoint.
Graybug Vision, a clinical stage pharmaceutical company developing potentially transformative long-acting therapies for ocular diseases including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), retinal vein occlusion (RVO), and primary open angle glaucoma (POAG), announced the initiation of its Phase 2a study with GB-102 in patients with macular edema (ME) secondary to DME or RVO.
Novartis said that the phase 3 trial of its psoriasis drug Cosentyx (secukinumab), called PREVENT, in patients with non-radiographic axial spondyloarthritis (nr-axSpA), has met its primary endpoint at Week 16.
Concert Pharmaceuticals announced that it has completed patient enrollment of an open label clinical trial to evaluate once-daily 24 mg compared to twice-daily 12 mg oral dosing of CTP-543 in patients with alopecia areata.
POXEL, a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced the initiation of a Phase 1b double-blind, randomized, placebo-controlled study in healthy subjects to evaluate the safety, tolerability and pharmacokinetics (PK) as well as support dose selection for a pivotal study of PXL065.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.